Cargando…
Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost
BACKGROUND: Authors from the Canadian Agency for Drugs and Technologies in Health (CADTH) presented an analysis of submissions to the Common Drug Review (CDR) between 2004 and February 3, 2016 for drugs for rare disorders (disorders with a prevalence of <50 per 100,000). OBJECTIVE: The aim of thi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363033/ https://www.ncbi.nlm.nih.gov/pubmed/28330479 http://dx.doi.org/10.1186/s13023-017-0611-7 |